Guangzhou Wondfo Biotech Co (300482) Fair Value & Analysis
Healthcare · CN · Market cap 9.8B CNY
Analysis
Guangzhou Wondfo Biotech Co (300482) currently trades at ¥19.05, while our model-based Fair Value estimate is ¥5.47 — implying the stock looks roughly 71.3% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP cam…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.